Botulinum Toxin Type A Injection for Management of Upper Limb Spasticity in Children with Cerebral Palsy: a Literature Review.
10.3349/ymj.2006.47.5.589
- Author:
Eun Sook PARK
1
;
Dong wook RHA
Author Information
1. Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Korea. pes1234@yumc.yonsei.ac.kr
- Publication Type:Review
- Keywords:
Cerebral palsy;
botulinum toxin type A;
spasticity;
upper limb
- MeSH:
Upper Extremity;
Range of Motion, Articular/drug effects;
Neuromuscular Agents/administration & dosage/*therapeutic use;
Muscle Spasticity/drug therapy;
Injections;
Infant;
Humans;
Child, Preschool;
Child;
Cerebral Palsy/*drug therapy;
Botulinum Toxin Type A/administration & dosage/*therapeutic use;
Age Factors;
Adult;
Adolescent
- From:Yonsei Medical Journal
2006;47(5):589-603
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this article was to present a review of the research literature on the outcome of botulinum toxin type A (BTX-A) injection for management of upper limb spasticity in children with cerebral palsy (CP). We searched the electronic databases of MEDLINE, CINAHL and PUBMED for all published studies with full-length English text available. For each study, the quality of the methods and the strength of evidence were assessed by 2 independent reviewers based on the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) guidelines. Four studies of level I, 8 studies of level IV and 4 studies of level V were identified. Due to the limited number of studies with high quality evidence and inconsistent results among studies, we were unable to support or refute the usefulness of BTX-A injection for management of upper limb spasticity in children with CP. Moreover, we identified several variables that may affect the outcome of injection, such as timing of age, dosage, dilution volumes, localization techniques of target muscles and participant characteristics. In summary, we have presented a review the literature and a discussion of the considerable uncertainty and variation associated with the clinical use of BTX-A injection for management of upper limb spasticity in children with CP.
